PT/INR Test: Prothrombin Time and International Normalized Ratio

Prothrombin Time (PT) and INR — scientific infographic poster

The Prothrombin Time (PT) measures how quickly blood clots through the extrinsic coagulation pathway — the route initiated by tissue factor after vessel injury. The International Normalized Ratio (INR) is a standardized calculation derived from the PT that corrects for differences in laboratory reagents, making warfarin monitoring consistent across institutions. Together, PT and INR are among the most frequently ordered coagulation tests in clinical medicine, serving triple duty: monitoring anticoagulant therapy, evaluating liver synthetic function, and assessing bleeding risk before procedures.

Table of Contents

  1. Overview — Extrinsic Coagulation Pathway
  2. How PT and INR Are Measured
  3. Normal and Therapeutic Ranges
  4. Pre-Procedure INR Thresholds
  5. Warfarin Therapy and INR Monitoring
  6. PT as a Liver Function Test
  7. Vitamin K and PT/INR
  8. Factor V Leiden and Coagulation Genetics
  9. Point-of-Care INR Testing
  10. Causes of Prolonged PT/INR
  11. aPTT: The Intrinsic Pathway Partner Test
  12. Urgent Reversal Strategies
  13. Key Research and Citations
  14. Connections
  15. Featured Videos

Overview — Extrinsic Coagulation Pathway

The extrinsic pathway is triggered when tissue factor (TF, Factor III) — normally expressed only on subendothelial cells — is exposed to circulating blood after vessel injury. TF binds Factor VII to form the TF-VIIa complex, which activates Factor X and Factor IX. Factor Xa, together with its essential cofactor Factor Va, assembles into the prothrombinase complex on the surface of activated platelets and phospholipid membranes. This complex converts prothrombin (Factor II) to thrombin at a rate approximately 300,000 times faster than Factor Xa alone. Thrombin then cleaves fibrinogen to fibrin monomers, which polymerize end-to-end and side-to-side, forming a loose gel. Factor XIII, also activated by thrombin, cross-links the fibrin polymers covalently, creating the stable, mechanically robust clot that anchors the platelet plug.

The PT measures this entire extrinsic and common pathway in a single number. A prolonged PT means clot formation is slower than normal, reflecting reduced activity of one or more factors in this chain. Because Factors I (fibrinogen), II (prothrombin), V, VII, and X are all synthesized exclusively in the liver, the PT is an exquisitely sensitive window into hepatic synthetic function. Additionally, Factors II (prothrombin), VII, IX, and X require vitamin K for the final post-translational step of gamma-carboxylation of glutamate residues. Without this modification, these proteins cannot bind calcium or phospholipid membranes effectively, making them functionally inert as coagulation factors. This dual sensitivity — to liver disease and to vitamin K status — gives the PT its broad clinical utility far beyond simple anticoagulation monitoring.

Factors Measured by the PT

The name "prothrombin time" is historically a misnomer — the test does not measure prothrombin (Factor II) in isolation. It reports the combined activity of the extrinsic-pathway factor (VII) and every factor of the common pathway (X, V, II, and fibrinogen/Factor I). A deficiency anywhere along that chain prolongs the result:

Understanding the extrinsic pathway also clarifies why Factor VII deficiency or depletion produces an isolated PT prolongation. Factor VII is unique to the extrinsic pathway; all other factors downstream (X, V, II, fibrinogen) are shared with the intrinsic pathway. The aPTT (activated partial thromboplastin time), which measures the intrinsic pathway, remains normal when only Factor VII is affected. Conversely, the PT and aPTT both prolong when common pathway factors (X, V, II, or fibrinogen) are depleted, as occurs in severe liver failure or disseminated intravascular coagulation (DIC).

The cascade model of coagulation described above — extrinsic, intrinsic, and common pathways — is useful for interpreting laboratory tests, but it is a simplification of in vivo hemostasis. The cell-based model of coagulation recognizes that tissue factor bearing cells initiate clotting, platelets amplify it, and propagation occurs on the platelet surface. However, the cascade model remains the framework for understanding PT and aPTT results clinically.

Back to Table of Contents

How PT and INR Are Measured

The prothrombin time was described by the American physician Armand Quick in 1935, in the same period that heparin was being developed for clinical anticoagulant use. Quick's original method — recalcify citrated plasma in the presence of a tissue extract and time the appearance of a clot — is, in principle, the method still in use today. Nearly a century of refinement has changed the reagents and the clot-detection hardware, not the underlying logic of the assay.

Blood is drawn into a blue-top tube containing sodium citrate (buffered 3.2% sodium citrate). Citrate is an anticoagulant that chelates free calcium ions, halting the coagulation cascade in the tube. The ratio of blood to citrate is critical — the standard ratio is 9:1 (blood:citrate). If the tube is underfilled, excess citrate relative to plasma causes falsely prolonged results; if the tube is overfilled or the patient has severe polycythemia (elevated hematocrit), the citrate concentration is relatively low. In patients with a hematocrit above 55%, the laboratory must use a corrected citrate volume, or the PT will be spuriously shortened.

In the laboratory, the citrated plasma is separated by centrifugation. The PT assay then proceeds in three steps: (1) the plasma is warmed to 37°C; (2) calcium chloride is added to overcome the citrate chelation; (3) thromboplastin — a mixture of human or recombinant tissue factor, phospholipid, and calcium — is added. The stopwatch starts. The time from thromboplastin addition to clot detection (via optical or electromechanical methods) is the PT in seconds.

The INR was introduced by the World Health Organization in 1983 to solve a persistent and dangerous problem: thromboplastin reagents from different manufacturers had wildly different sensitivities to Factor VII depletion. Early rabbit-brain thromboplastins were less sensitive than later human placental or recombinant preparations. A patient anticoagulated at exactly the same therapeutic level might have a PT of 18 seconds at one hospital using a sensitive reagent and 26 seconds at another hospital using an insensitive reagent. Clinicians using raw PT seconds to titrate warfarin were inadvertently over- or under-anticoagulating patients depending on which hospital they used.

The INR solves this by incorporating the International Sensitivity Index (ISI) assigned to each lot of thromboplastin reagent by the manufacturer through calibration against a WHO international reference preparation. The formula is: INR = (Patient PT ÷ Mean Normal PT)ISI. The Mean Normal PT (MNPT) is the geometric mean PT of at least 20 healthy adult volunteers run on the same instrument with the same reagent lot. A perfectly calibrated assay with an ISI of 1.0 yields an INR numerically equal to the raw PT ratio. The lower the ISI, the more sensitive the reagent and the less exponential correction the formula has to apply. Modern recombinant thromboplastin reagents typically have ISI values between 0.9 and 1.1, making INR and PT ratio nearly equivalent. Older rabbit-brain reagents had ISI values as high as 2.8, which required substantial correction.

Two limitations of the INR are worth stating plainly, because they are routinely overlooked. First, the INR was derived and validated for one purpose — monitoring vitamin K antagonist therapy in patients whose livers work — and it performs reliably only in that context. Second, the INR is not a bleeding-risk meter. It is a clotting-speed measurement that happens to correlate with bleeding risk in warfarin-treated patients, and that correlation does not transfer to liver disease, DIC, or direct oral anticoagulants.

Point-of-care analyzers (whole blood finger-prick devices) use dry reagent strips and electrochemical clot detection. They calculate INR using a device-specific ISI. Multiple studies have shown strong correlation with laboratory INR (Pearson r > 0.97, mean bias typically under 0.2 INR units), sufficient for clinical management. However, they should not be used to diagnose coagulopathies other than warfarin effect, and results in patients with lupus anticoagulant or extreme polycythemia/anemia may be unreliable.

Back to Table of Contents

Normal and Therapeutic Ranges

Reference ranges vary slightly between laboratories, but widely accepted values are:

Therapeutic INR targets by indication (per ACCP, ACC/AHA, and ASH guidelines):

INR values above the therapeutic range carry progressively increasing bleeding risk:

A useful clinical heuristic: the risk of clinically significant bleeding roughly doubles for each 0.5-unit rise in INR above 3.0 in patients on warfarin. An INR of 6.0 confers approximately 8-fold higher bleeding risk compared to a therapeutic INR of 2.5.

Back to Table of Contents

Pre-Procedure INR Thresholds

An INR above 1.5 is the threshold most commonly cited as a reason to pause before an invasive procedure. It is a convention rather than a validated cut-off: the actual bleeding risk depends far more on the procedure than on the number. A liver biopsy, a spinal anesthetic, and a cardiac catheterization each place a different premium on hemostasis, and the evidence linking a mildly abnormal coagulation screen to actual procedural bleeding is thinner than the ubiquity of the 1.5 threshold suggests (Segal and Dzik reviewed this literature in 2005 and found remarkably little of it).

With that caveat, the thresholds in general institutional use are:

Two further orientation points on the scale: an INR above 2.0 is supratherapeutic for most warfarin patients who do not have a mechanical valve, and an INR above 5.0 carries a high risk of serious spontaneous bleeding and warrants urgent reversal (see Urgent Reversal Strategies).

Back to Table of Contents

Warfarin Therapy and INR Monitoring

Warfarin (Coumadin) has been the mainstay of oral anticoagulation for over six decades. It acts by inhibiting vitamin K epoxide reductase complex subunit 1 (VKORC1), the enzyme that recycles oxidized vitamin K epoxide back to its active reduced (hydroquinone) form. Without active vitamin K, the gamma-carboxylation of glutamic acid residues on Factors II, VII, IX, and X (as well as the anticoagulant proteins C and S) is blocked. These under-carboxylated proteins are called PIVKA (Proteins Induced by Vitamin K Absence or Antagonism) and are functionally inactive in the coagulation cascade.

The onset and offset of warfarin anticoagulation are governed by the half-lives of the affected coagulation factors:

This dissociation between early INR rise (driven by Factor VII depletion) and true anticoagulation (requiring prothrombin depletion) is why bridging with a parenteral anticoagulant (heparin or LMWH) was historically used when initiating warfarin for acute DVT or PE. Current guidelines (ACCP 2016) no longer routinely recommend heparin bridging for non-valvular AF in patients starting or temporarily stopping warfarin.

Drug interactions with warfarin are extensive and clinically important. Warfarin is predominantly metabolized by CYP2C9 (S-warfarin, the more potent enantiomer) and CYP3A4 (R-warfarin). Inhibitors of these enzymes increase warfarin exposure and raise the INR:

Inducers of CYP enzymes reduce warfarin effect and lower the INR:

Dietary vitamin K is a frequent source of INR variability. High-vitamin K foods (kale, spinach, broccoli, Brussels sprouts, Swiss chard, collard greens) oppose warfarin's effect. The key clinical principle is consistency, not avoidance. Patients who eat a consistent amount of leafy greens will have a stable INR, even at a high vitamin K intake, because the warfarin dose can be adjusted accordingly. Sudden large increases in dietary vitamin K (e.g., beginning a green smoothie habit) lower the INR; sudden cessation raises it.

Acute illness is an underappreciated source of INR instability. Fever raises the catabolic rate of clotting factors; diarrhea impairs absorption of both warfarin and dietary vitamin K and disturbs the gut flora that make vitamin K2; and reduced oral intake during any illness cuts vitamin K1 supply. Each of these pushes the INR up, and they frequently arrive together, which is why a patient who was rock-steady for a year can present with an INR of 6 after a week of gastroenteritis. Any significant intercurrent illness in a warfarin patient is a reason to recheck the INR sooner than the routine schedule would call for.

Pharmacogenomics of warfarin: Two genes account for most of the interindividual variability in warfarin dosing:

The FDA warfarin label (updated 2010) recommends considering genotyping when initiating warfarin. The EU PHAR study and COAG trial showed mixed results on whether genotype-guided dosing reduces adverse events versus clinical algorithms, but pharmacogenomic dosing reduces early supratherapeutic INR and bleeding in the first 90 days.

Time in therapeutic range (TTR) is the single most useful quality metric for warfarin management — more informative than any individual INR result. It is the proportion of time a patient's INR sits inside the target window, conventionally calculated by the Rosendaal linear-interpolation method. A TTR above 65–70% is associated with substantially lower rates of both thrombotic and hemorrhagic events, and warfarin managed to that standard approaches the outcomes seen with DOACs in the major atrial fibrillation trials. A persistently poor TTR — despite good adherence and a stable diet — is one of the strongest arguments for switching a patient to a direct oral anticoagulant.

Direct oral anticoagulants (DOACs) — rivaroxaban, apixaban, edoxaban (Factor Xa inhibitors) and dabigatran (direct thrombin inhibitor) — have replaced warfarin for most indications including non-valvular AF and VTE. Their fixed dosing, predictable pharmacokinetics, fewer drug interactions, and the absence of routine INR monitoring have made them the first-line choice in multiple guideline updates. Warfarin retains its role for patients with mechanical heart valves (DOACs are contraindicated), antiphospholipid syndrome with triple positivity (evidence of harm with DOACs), severe CKD (GFR < 15–25, where most DOACs are not studied), and patients who cannot afford newer agents.

Back to Table of Contents

PT as a Liver Function Test

The liver is the exclusive site of synthesis for virtually all coagulation factors. The major exceptions are Factor VIII and von Willebrand factor, both produced by vascular endothelium (and megakaryocytes for vWF). This means that impaired hepatic synthetic function — whether from acute liver failure, decompensated cirrhosis, or hepatitis-induced injury — rapidly depletes clotting factors and prolongs the PT. The PT is among the earliest and most sensitive markers of hepatic synthetic failure, appearing before hypoalbuminemia (albumin half-life ~20 days), before hyperbilirubinemia (which also reflects excretory dysfunction), and before overt coagulopathy is clinically apparent.

The PT/INR is incorporated into two key prognostic scoring systems for liver disease:

The INR term carries a large coefficient in MELD (11.2), which makes the score unusually sensitive to it — and that is a recognized structural flaw. Thromboplastin reagents are calibrated against warfarin-treated plasma, not against the coagulopathy of liver disease, and the two mechanisms are not the same: warfarin depletes a specific set of vitamin K-dependent factors, while cirrhosis depresses synthesis across the board. The consequence is that two patients with identical hepatic synthetic function can receive materially different MELD scores depending solely on which reagent their local laboratory happens to stock, and therefore different positions on a transplant waiting list. This has driven proposals for liver-specific coagulation indices — an INR calibrated on cirrhotic rather than warfarin plasma (the so-called INRliver), or replacement of the INR term altogether with a thrombin generation assay or a direct Factor V level.

An important limitation: the INR is validated only for warfarin monitoring in patients with normal liver function. In patients with cirrhosis, the standard INR is NOT a reliable measure of actual bleeding risk. Cirrhotic patients have complex hemostatic rebalancing — they are simultaneously deficient in pro-coagulant factors (II, V, VII, X) but also deficient in anti-coagulant proteins (protein C, protein S, antithrombin), and they have elevated vWF and reduced ADAMTS13. The result is a fragile equilibrium that the INR does not capture. A cirrhotic patient with an INR of 1.8 may be perfectly hemostatic in vivo despite the elevated lab value. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provide better real-time assessment of whole-blood clotting in this population, and frequently show near-normal global clot formation in clinically stable cirrhosis despite an alarming-looking INR.

This has a direct practical consequence: transfusing fresh frozen plasma purely to "correct" the INR before a procedure in a stable cirrhotic patient is usually unnecessary and is not harmless. Plasma is a large-volume product; in a patient with portal hypertension it raises portal pressure and can precipitate variceal bleeding, and it carries the standard transfusion hazards including volume overload and transfusion-related acute lung injury. Contemporary hepatology guidance discourages prophylactic plasma transfusion aimed at an INR target in stable cirrhosis, and directs attention instead to fibrinogen level, platelet count, and viscoelastic testing.

Acute liver failure (ALF) — a catastrophic syndrome of acute hepatic necrosis with encephalopathy — is defined in part by an INR above 1.5 (King's College criteria use INR > 6.5 as a poor prognosis indicator for acetaminophen ALF, or INR > 3.5 plus bilirubin > 17.5 mg/dL for non-acetaminophen ALF). Factor V levels, which reflect only synthetic function without vitamin K influence, are particularly useful in this setting — the Clichy criteria use Factor V < 20% in patients under 30, or < 30% in patients over 30, as an indicator for transplant listing.

Neonates normally have a mildly prolonged PT (11–15 seconds) at birth, reflecting both immature hepatic synthesis and relative vitamin K deficiency. This is physiologic and corrects within days with standard vitamin K supplementation.

Back to Table of Contents

Vitamin K and PT/INR

Vitamin K is a fat-soluble vitamin named for the German word Koagulationsvitamin, reflecting its essential role in blood clotting — identified by Danish biochemist Henrik Dam in the 1920s. It exists in two primary dietary forms with distinct sources and bioavailabilities:

The biochemical role of vitamin K is as the essential cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that adds a carboxyl group to specific glutamate residues (Gla residues) on vitamin K-dependent proteins. This reaction requires vitamin K hydroquinone (KH2) and converts it to vitamin K epoxide (K>O). The vitamin K cycle: K>O is recycled to K by vitamin K epoxide reductase (VKOR1), then to KH2 by either VKOR1 or DT-diaphorase. Warfarin blocks the VKOR1 step.

Vitamin K deficiency produces a predictable sequence of PT/INR changes governed by factor half-lives:

  1. Within 24–48 hours of severe deficiency: Factor VII (half-life 4–6 h) falls — PT/INR prolongs; aPTT remains normal. This is identical to the initial effect of warfarin.
  2. By 48–72 hours: Factors IX and X (half-life 24–48 h) decline — aPTT begins to prolong.
  3. By 4–5 days: Prothrombin (half-life 60–72 h) falls — full coagulopathy established; both PT and aPTT significantly prolonged.
  4. Fibrinogen and Factor V are unaffected (not vitamin K-dependent).

The PT/aPTT pattern (PT prolonged, aPTT normal → then both prolonged, fibrinogen normal) distinguishes vitamin K deficiency from DIC (where fibrinogen is consumed) and heparin (which prolongs aPTT >> PT).

Causes of clinical vitamin K deficiency include:

Treatment of vitamin K deficiency (non-warfarin): oral or IV vitamin K1. IV administration (phytonadione) is faster but carries a small risk of anaphylactoid reactions (give slowly over 20–60 minutes, diluted). Oral dosing (2.5–25 mg) is effective for most non-emergent situations and reverses PT prolongation within 12–24 hours. Subcutaneous vitamin K is absorbed erratically and is no longer recommended.

Back to Table of Contents

Factor V Leiden and Coagulation Genetics

Factor V Leiden is the most prevalent inherited thrombophilia in populations of European ancestry, with a heterozygous carrier frequency of approximately 5% (1 in 20 individuals) and homozygous frequency of about 1 in 1,000. The mutation is a single nucleotide change at position 1691 in the Factor V gene (G→A), producing an arginine-to-glutamine substitution at amino acid position 506 (R506Q). This site is the primary cleavage site where activated Protein C (APC) normally inactivates Factor Va, terminating thrombin generation. The Leiden mutation makes Factor Va resistant to APC cleavage, resulting in prolonged thrombin generation and a net hypercoagulable state.

The thrombotic risk increase depends on zygosity and clinical context:

The PT and INR are typically normal in Factor V Leiden heterozygotes and homozygotes. The mutation increases thrombotic risk but does not impair clot formation speed (the PT measures clot formation, not clot dissolution or regulation). The APC resistance assay (a functional test measuring the ratio of aPTT with and without exogenous APC) and direct genetic PCR testing are the appropriate diagnostic methods.

Other inherited thrombophilias relevant to the coagulation testing context:

When evaluating for hereditary thrombophilia, the timing of testing matters. Acute thrombosis, pregnancy, OCP use, and acute illness all alter protein levels and may produce falsely abnormal or falsely normal results. Warfarin therapy reduces levels of all vitamin K-dependent proteins (Protein C, S, and coagulation factors). Testing is ideally performed 4–6 weeks after completing anticoagulation and in a clinical steady state.

Back to Table of Contents

Point-of-Care INR Testing

Self-monitoring of anticoagulation with home INR devices represents one of the most successful applications of point-of-care testing in chronic disease management. Two FDA-approved devices dominate the US market: the Roche CoaguChek XS (optical reflectance, liquid crystal display) and the now-discontinued INRatio2 (replaced by similar devices). Both analyze a small whole-blood sample (5–10 µL) from a fingerstick and produce a result in 60–120 seconds.

The technology works as follows: the test strip contains dried thromboplastin reagent. Blood applied to the strip reactivates the reagent. An optical or electrochemical sensor detects the change in blood properties as a clot forms and calculates the clotting time. The device applies a device-specific ISI to convert the clotting time to an INR. Each device is calibrated to the international thromboplastin reference standard.

Analytical performance: multiple comparative studies and meta-analyses have shown that point-of-care INR devices correlate closely with laboratory INR (Pearson r typically 0.97–0.99, mean absolute bias 0.1–0.3 INR units). In a large systematic review by Heneghan et al. (2012), POC devices were accurate across the therapeutic range (INR 1.5–4.5) but showed reduced reliability at very high INR values (>4.5) and in patients with elevated hematocrit, lupus anticoagulant, or lipaemic samples.

Patient self-management (PSM) programs allow patients to not only self-test but also self-adjust their warfarin dose based on a predefined algorithm, with provider oversight. The evidence base for PSM is robust:

Insurance coverage and patient selection: Medicare covers POC INR testing (CPT 93793) for patients with mechanical heart valves; commercial insurance coverage is variable. Ideal candidates are motivated patients with stable warfarin requirements, good manual dexterity, ability to understand and follow a dosing algorithm, and reliable follow-up. Patients with cognitive impairment, poor compliance history, or unstable INR due to comorbidities are not good candidates.

Limitations of POC INR testing:

Back to Table of Contents

Causes of Prolonged PT/INR

A systematic approach to PT/INR prolongation considers whether the aPTT is normal or also prolonged, whether fibrinogen is affected, and the clinical context:

Isolated PT prolongation (aPTT normal, fibrinogen normal):

Both PT and aPTT prolonged (fibrinogen normal or elevated):

Both PT and aPTT prolonged with low fibrinogen and elevated D-dimer:

Spuriously prolonged PT (artifact):

Interpretation tip — the mixing study: When the cause of PT or aPTT prolongation is unclear, mixing the patient's plasma 1:1 with normal pooled plasma and re-running the test identifies whether the prolongation is due to a factor deficiency (mixing corrects it) or an inhibitor (mixing fails to correct, or shows a characteristic "incubated mixing study" correction failure for time-sensitive inhibitors like Factor VIII inhibitors).

Back to Table of Contents

aPTT: The Intrinsic Pathway Partner Test

The PT is almost never interpreted alone. Its partner test, the activated partial thromboplastin time (aPTT), measures the intrinsic pathway (Factors XII, XI, IX, and VIII) together with the same common pathway the PT covers (X, V, II, and fibrinogen). Reading the two together is what converts a prolonged clotting time into a differential diagnosis.

The aPTT is performed by adding three things to citrated plasma: an activating agent (kaolin, ellagic acid, or micronized silica — the "activated" in the name), a phospholipid source without tissue factor (the "partial thromboplastin"), and calcium. Because no tissue factor is supplied, the reaction must start through contact activation, which is what makes the assay report on the intrinsic limb. A typical reference range is 25–38 seconds, laboratory-specific as always.

A prolonged aPTT with a normal PT localizes the defect to the intrinsic pathway:

Combining the two tests gives a compact decision table: PT prolonged with normal aPTT points to Factor VII (warfarin, early vitamin K deficiency, early liver disease); aPTT prolonged with normal PT points to the intrinsic factors or heparin; both prolonged points to the common pathway, to advanced liver failure, to severe vitamin K deficiency, or — when fibrinogen is low and D-dimer high — to DIC. When either test is unexpectedly prolonged, the mixing study described in the previous section is the next step in every case.

Back to Table of Contents

Urgent Reversal Strategies

When warfarin-associated coagulopathy causes life-threatening bleeding or an operation cannot wait, anticoagulation has to be undone quickly. The choice of agent is dictated by how fast the correction is needed and how much volume the patient can tolerate.

4-Factor Prothrombin Complex Concentrate (4F-PCC)

4F-PCC — marketed as Kcentra in the United States and as Beriplex or Octaplex elsewhere — is a plasma-derived concentrate of all four vitamin K-dependent procoagulant factors (II, VII, IX, and X) plus the anticoagulant proteins C and S. It corrects the INR to below 1.5 within roughly 15–30 minutes of infusion, and it does so in a small volume, typically 25–50 mL, which is the decisive advantage over plasma in an elderly patient with an intracranial hemorrhage and a marginal ejection fraction. It is the first-line agent for urgent reversal in life-threatening bleeding — intracranial hemorrhage, major gastrointestinal bleeding with hemodynamic compromise — and before emergency surgery. Dosing is weight- and INR-based. Always give intravenous vitamin K1 alongside it: the infused factors are cleared over the following hours while warfarin is still on board, so without vitamin K to restore endogenous synthesis the INR rebounds. The Sarode trial established 4F-PCC as non-inferior to plasma for hemostatic efficacy and superior for speed of INR correction.

Fresh Frozen Plasma (FFP)

FFP contains every coagulation factor, but at physiological rather than concentrated levels, so meaningful INR correction requires 10–20 mL/kg — typically 4 to 6 units, or 1,000–1,500 mL. It must be thawed (20–30 minutes) and ABO-compatible, which adds delay at exactly the moment delay is most costly. Compared with 4F-PCC it is slower, less complete, and carries the risks of volume overload and transfusion-related acute lung injury (TRALI). It remains the right choice when PCC is unavailable, when the patient needs factors that PCC does not contain — Factor V above all — and as part of a massive transfusion protocol alongside red cells and platelets in a balanced 1:1:1 ratio.

Vitamin K1 (Phytonadione)

Vitamin K1 does not act by replacing factors; it restores the substrate the liver needs to make them, so its effect is inherently delayed but durable. Given orally it lowers an elevated INR over roughly 24 hours, and intravenously — infused slowly and diluted, because of the small risk of an anaphylactoid reaction — within about 6–12 hours. For asymptomatic INR elevation, holding warfarin with or without low-dose oral vitamin K (1–2.5 mg) is standard; for minor bleeding at a high INR, 2.5–5 mg orally is appropriate; the intravenous route is reserved for serious bleeding, for emergency reversal alongside 4F-PCC, and for situations where oral absorption cannot be relied on. Subcutaneous administration is absorbed too erratically to be recommended.

Reversal of Direct Oral Anticoagulants

The DOACs do not belong on this page's monitoring scale at all: rivaroxaban, apixaban, and edoxaban (direct Factor Xa inhibitors) and dabigatran (a direct thrombin inhibitor) prolong the PT and aPTT unpredictably, and neither test is validated for measuring their effect. A normal PT does not exclude a therapeutic DOAC level. Reversal uses agent-specific antidotes: idarucizumab (Praxbind), a monoclonal antibody fragment, for dabigatran, and andexanet alfa (Andexxa), a decoy Factor Xa molecule, for the anti-Xa agents. Where the specific agent is unavailable, 4F-PCC is used as a non-specific reversal strategy. Dabigatran, uniquely among the DOACs, is also dialyzable.

Back to Table of Contents

Key Research and Citations

  1. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133(6 Suppl):160S–198S. PMID: 18574265
  2. Hirsh J, Dalen J, Anderson DR, et al. Managing oral anticoagulant therapy. Chest. 2001;119(1 Suppl):22S–38S. PMID: 11157641
  3. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Chest. 2012;141(2 Suppl):e419S–e496S. PMID: 22315268
  4. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(Suppl 1):S141–S145. PMID: 22473649
  5. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–156. PMID: 21751907
  6. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. PMID: 19966341
  7. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Chest. 2012;141(2 Suppl):e152S–e184S. PMID: 22315269
  8. Dahlback B. Blood coagulation. Lancet. 2000;355(9215):1627–1632. — Search PubMed
  9. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44–e164. Reference for warfarin AF management: Wann LS et al. 2011 ACCF/AHA/HRS focused update. J Am Coll Cardiol. 2011;57(2):223–242. — Search PubMed
  10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. PMID: 19717844
  11. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222–1231. PMID: 11309638
  12. Tripodi A. The international normalized ratio. Clin Chem. 2007;53(7):1260–1261. — Search PubMed
  13. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41(9):1633–1652. PMID: 12742309
  14. Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem. 1935;109:73–74. (Historical — the original description of the prothrombin time; accessible through the Journal of Biological Chemistry archives.)
  15. Segal JB, Dzik WH; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures. Transfusion. 2005;45(9):1413–1425. PMID: 16131373
  16. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–1330. PMID: 11816725
  17. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243. PMID: 23935011
  18. Nuttall GA, Brost BC, Connis RT, et al. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105(1):198–208. — Search PubMed
  19. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–204. — Search PubMed
  20. Nishijima DK, Shahlaie K, Sarkar K, et al. Elevated admission international normalized ratio and outcomes after traumatic brain injury. — Search PubMed
  21. Weitz JI, Semchuk W, Turpie AG, et al. Trends in prescribing oral anticoagulants in Canada, 2008–2014. Clin Ther. 2015;37(11):2506–2514. — Search PubMed
  22. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730–2735. — Search PubMed

PubMed searches for further reading:

  1. Warfarin INR monitoring therapeutic range — PubMed
  2. Prothrombin time liver disease MELD score — PubMed
  3. Factor V Leiden thrombophilia VTE risk — PubMed
  4. Point-of-care INR patient self-management — PubMed
  5. Vitamin K deficiency coagulopathy treatment — PubMed
  6. Prothrombin complex concentrate warfarin reversal — PubMed
  7. Disseminated intravascular coagulation diagnosis criteria — PubMed
  8. aPTT intrinsic pathway hemophilia lupus anticoagulant — PubMed
  9. PT/INR liver disease cirrhosis coagulopathy — PubMed

Back to Table of Contents

Connections

Back to Table of Contents